Posted On: 01/12/2014 5:31:05 PM
Post# of 7769
I've been in the pharmaceutical industry for over 35 years. This is what I have seen. Glaxo/GSK (PPS $52.75), Amgen (PPS $117.99), Jazz PPS $138.56), now let's see, next in line, ScripsAmerica. The only negative commentary I can make is SCRC has too many letters in it's name. So what did/do all these companies have in common, they all had a CEO with a dream, they all started out small, and they all had one product that put them on the map. I was with Glaxo when they launched Zantac and no one ever accurately predicted how big that drug would be. I believe the same holds true for ScripsAmerica and RapiMeds. Once launched, the generated revenues will blow everyone's mind.
(0)
(0)
